Progressive attenuation of the firing activity of locus coeruleus noradrenergic neurons by sustained administration of selective serotonin reuptake inhibitors

International Journal of Neuropsychopharmacology

Volumn 3, Issue 1, 2000, Pages 1-11

  Szabo, Steven T ^a,b   De Montigny, Claude ^a   Blier, Pierre ^b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Antidepressant; Major depression; Noradrenaline; Panic disorder; Serotonin; SSRI

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; ALCOHOL; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CITALOPRAM; DESIPRAMINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PAROXETINE; RITANSERIN; SEROTONIN UPTAKE INHIBITOR; WATER;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE TIME EFFECT RELATION; LOCUS CERULEUS; MALE; NONHUMAN; NORADRENERGIC NERVE; OSMOTIC MINIPUMP; PANIC; PRIORITY JOURNAL; RAT; RECEPTOR DOWN REGULATION; SEROTONINERGIC TRANSMISSION;

EID: 0034130674     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145700001772     Document Type: Article

References (58)

1. Anderson C, Pasquier DA, Forbes WB, Morgane PJ (1977). Locus coeruleus-to-dorsal raphe input examined by electrophysiological and morphological methods. Brain Research Bulletin 2, 209-221.
2. Aston-Jones G, Akaoka H, Charlety P, Chouvet G (1991). Serotonin selectively attenuates glutamate-evoked activation of noradrenergic locus coeruleus neurons. Journal of Neuroscience 11, 760-769.
3. 1A to selectively atttenuate glutamate-evoked responses of locus coeruleus neurons. Society for Neuroscience Abstracts 16, 799.
4. 2C receptors, respectively. Neuropsychopharmacology 13, 1-8.
5. 3 antagonist ondansetron reduces gastrointestinal side effects induced by a specific serotonin re-uptake inhibitor in man. Journal of Clinical Psychopharmacology 16, 35-37.
6. Baraban JM, Aghajanian GK (1980). Suppression of serotonergic neuronal firing by alpha-adrenoceptor antagonists: evidence against GABA mediation. European Journal of Pharmacology 66, 287-294.
7. Béïque JC, de Montigny C, Blier P, Debonnel G (1998). Blockade of 5-HT and NE reuptake by venlafaxine: a comparative study with paroxetine and desipramine. British Journal of Pharmacology 125, 526-532.
8. Béïque JC, de Montigny C, Blier P, Debonnel G (1999). Venlafaxine: discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites. Synapse 32, 198-211.
9. Bergeron R, Blier P (1994). Cisapride for the treatment of nausea produced by selective serotonin reuptake inhibitors. American Journal of Psychiatry 151, 1084-1086.
10. Blier P, de Montigny C (1980). Effect of chronic tricyclic antidepressant treatment on the serotonergic autoreceptor: a microiontophoeretic study in the rat. Naunyn-Schmiedebergs Archives of Pharmacology 314, 123-128.
11. Blier P, de Montigny C (1983). Electrophysiological investigations on the effect of repeated zimelidine administration on serotonergic neurotransmission in the rat. Journal of Neuroscience 3, 1270-1278.
12. Blier P, de Montigny C (1994). Current advances and trends and treatment of depression. Trends in Pharmacological Science 15, 220-226.
13. Blier P, de Montigny C (1997). Serotonergic neurons and 5-HT receptors in the CNS. Handbook of Experimental Pharmacology 129, 727-750.
14. Bolden-Watson C, Richelson E (1993). Blockade by newly developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Science 52, 1023-1029.
15. 1A receptors. Comptes Rendus de l'Académie des Sciences 312, 421-426.
16. Charney DS, Heninger GR (1986). Abnormal regulation of noradrenergic function in panic disorders. Effects of clonidine in healthy subjects and patients with agoraphobia and panic diorder. Archives in General Psychiatry 43, 1042-1054.
17. Charney DS, Heninger GR, Breier A (1984). Noradrenergic function in panic anxiety: effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Archives of General Psychiatry 43, 1155-1161.
18. 2 agonist augments γ-aminobutyric acid and excitatory amino acid inputs to noradrenergic locus coeruleus neurons. Neuroscience 54, 417-420.
19. Clement HW, Gemsa D, Wesemann W (1992). Serotonin-norepinephrine interactions: a voltammetric study on the effect of serotonin receptor stimulation followed in the nucleus raphe dorsalis and the locus coeruleus of the rat. Journal of Neural Transmission 88, 11-23.
20. Connor KM, Davidson JR (1998). Generalized anxiety disorder: neurobiological and pharmacotherapeutic perspectives. Biological Psychiatry 15, 1286-1294.
21. Danish University Antidepressant Group (1986). Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology 90, 131-138.
22. Danish University Antidepressant Group (1990). Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Journal of Affective Disorders 18, 289-299.
23. Davidson JRT (1998). Pharmacotherapy of social anxiety disorder. Journal of Clinical Psychiatry 59, 47-51.
24. de Montigny C, Blier P, Caillé G, Kouassi E (1981). Pre-and postsynaptic effect of zimelidine and norzimelidine on the serotonergic system: single cell studies in the rat. Acta Psychiatrica Scandinavica 63, S79-S80.
25. Depue RA, Spoont MR (1986). Conceptualizing a serotonin trait. A behavioral dimension of constraint. Annals of the New York Academy of Sciences 487, 47-62.
26. Einarson TR, Arikian SR, Casciano J, Doyle JJ (1999). Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials. Clinical Therapeutics 21, 296-308.
27. Feighner JP, Boyer WF (1991). Side effects of the selective serotonin re-uptake inhibitors. In: Selective Serolonin Reuptake Inhibitors (pp. 133-152). New York: John Wiley and Sons.
28. Fuller RW (1994). Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis. Life Science 55, 163-167.
29. Göthert M, Huth H, Schlicker E (1981). Characterization of the receptor subtype involved in alpha-adrenoceptor-mediated modulation of serotonin release from rat brain cortex slices. Naunyn-Schmiedebergs Archives of Pharmacology 317, 199-203.
30. Haddjeri N, de Montigny C, Blier P (1997). Modulation of the firing activity of noradrenergic neurones in the rat locus coeruleus by the 5-hydroxytryptamine system. British Journal of Pharmacology 120, 865-875.
31. Hyttel J (1982). Citalopram. Basic studies. Pharmacological profile of a specific uptake inhibitor with antidepressant activity. Progress in Neuropsychopharmacology Biological Psychiatry 6, 277-295.
32. Jefferson JW (1998). Antidepressants and panic disorder. Journal of Clinical Psychiatry 58, 20-25.
33. Kaehler, ST, Singewald N, Philippu A (1999). Dependence of serotonin release in the locus coeruleus on dorsal raphe neuronal activity. Naunyn-Schmiedebergs Archives of Pharmacology 359, 386-393.
34. Loizou LA (1969). Projections of the nucleus locus coeruleus in the albino rat. Brain Research 15, 563-569.
35. 2A receptors. Psychopharmacology 117, 193-199.
36. Mongeau R, Weiss M, de Montigny C, Blier P (1998). Effects of acute, short-and long-term milnacipran administration on rat locus coeruleus noradrenergic and dorsal raphe serotonergic neurons. Neuropsychopharmacology 37, 905-918.
37. Montgomery SA, Rasmussen JGC, Tanghoj P (1993). A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. International Clinical Psychopharmacology 8, 181-188.
38. Newman ME, Lerer B (1998). Chronic electroconvulsive shock and desimipramine reduce the degree of inhibition by 5-HT and carbachol of forskolin-stimulated adenylate cyclase in rat hippocampal membranes. European Journal of Pharmacology 148, 257-260.
39. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB (1997). Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. Journal of Pharmacology and Experimental Therapeutics 283, 1305-1322.
40. Page ME, Abercrombie ED (1997). An analysis of the effects of acute and chronic fluoxetine in extracellular norepinephrine in the rat hippocampus during stress. Neuropsychopharmacology 16, 419-425.
41. 1A agonist correlates with dopamine antagonist properties. Journal of Pharmacology and Experimental Therapeutics 268, 1297-1303.
42. Poirier MF, Boyer P (1999). Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. British Journal of Psychiatry 175, 12-16.
43. Post RM, Rubinow DR, Uhde TW, Roy-Byne PP, Linnoila M, Rosoff A, Cowdry R (1989). Dysmorphic mania. Clinical and biological correlates. Archives of General Psychiatry 46, 353-358.
44. Quinaux N, Scuvée-Moreau J, Dresse A (1982). Inhibition of in vitro and ex vivo uptake of noradrenaline and 5-hydroxytryptamine by five antidepressants; correlation with reduction of spontaneous firing rate of central monoaminergic neurones. Naunyn-Schmiedebergs Archives of Pharmacology 319, 66-70.
45. Rasmussen K, Aghajanian GK (1988). Potency of antipsychotics in reversing the effects of a hallucinogenic drug on locus coeruleus neurons correlates with 5-HT2 binding affinity. Neuropsychopharmacology 1, 101-107.
46. Silverstone PH, Ravindran A (1999). Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety (Venlafaxine XR 360 Study Group). Journal of Clinical Psychiatry 60, 22-28.
47. Stanford SC (1996). Prozac: panacea or puzzle? Trends in Pharmacological Science 17, 150-154.
48. 1A autoreceptor in the midbrain of suicide victims with major depression -postmortem evidence for decreased serotonin activity. Journal of Neuroscience 18, 7394-401.
49. Svensson TH, Usdin T (1978). Feedback inhibition of brain noradrenaline neurons by tricyclic antidepressants: alpha-receptor mediation. Science 202, 1089-1091.
50. Swann AC, Secunda S, Davis JM, Robins E, Hanin I, Koslow SH, Maas JW (1983). CSF monoamines metabolites in mania. American Journal of Psychiatry 140, 396-400.
51. Swann AC, Secunda S, Koslow SH, Katz MM, Bowden CL, Maas JW, Davis JM, Robins E (1991). Mania: sympathoadrenal function and clinical state. Psychiatry Research 37, 195-205.
52. Szabo ST, de Montigny C, Blier P (1999). Modulation of noradrenergic neuronal firing by selective serotonin reuptake blockers. British Journal of Pharmacology 126, 568-571.
53. Taylor CB (1995). Treatment of anxiety disorders. In: Schatzberg FA, Nemeroff CB (Eds.), The American Psychiatric Press Textbook of Psychopharmacology (pp. 641-655). Washington, DC: American Psychiatric Press.
54. Thomas ND, Nutt D, Holman BR (1998). Sertraline, a selective serotonin reuptake inhibitor modulates extracellular noradrenaline in the rat frontal cortex. Journal of Psychopharmacology 12, 366-370.
55. Todd KG, McManus DJ, Baker GB (1995). Chronic administration of the antidepressant phenelzine, desipramine, clomipramine, or maprotiline decreases binding to 5-hydroxytryptamine2A receptors without affecting benzodiazepine binding sites in the rat brain. Cellular and Molecular Neurobiology 35, 361-370.
56. Valentino RJ, Curtis AL, Parris DG, Wehby RG (1990). Antidepressant actions on brain noradrenergic neurons. Journal of Pharmacology and Experimental Therapeutics 253, 833-840.
57. Westenberg HG (1996). Developments in the drug treatment of panic disorder: what is the place of the selective serotonin reuptake inhibitors? Journal of Affective Disorders 40, 85-93.
58. Yamada S, Watanabe A, Nankai M, Toru M (1995). Acute immobilization stress reduces (±)-DOI-induced 5-HT2A receptor-mediated head shakes in rats. Psychopharmacology 119, 9-14.